BiotechTube
Home/Pipeline/AQ280

AQ280

Eosinophilic Esophagitis (EoE)

Phase 1/PreclinicalActive

Key Facts

Indication
Eosinophilic Esophagitis (EoE)
Phase
Phase 1/Preclinical
Status
Active
Company
Aqilion

About Aqilion

Aqilion is a publicly traded Swedish biotech specializing in early-stage drug development for chronic inflammatory and autoimmune diseases. The company operates a virtual or asset-centric model, advancing a small pipeline of internally developed small molecule candidates, with lead programs AQ280 and AQ128 poised for clinical development. Its strategy is to de-risk innovative science through preclinical and early clinical proof-of-concept before seeking partnerships or out-licensing to larger pharmaceutical companies for late-stage development and commercialization.

View full company profile

Therapeutic Areas

Chronic Inflammatory DiseasesAutoimmune Diseases

Other Eosinophilic Esophagitis (EoE) Drugs

DrugCompanyPhase
APT-1011Ellodi PharmaceuticalsPhase 3
ESO-101EsoCapPhase 2
'1104Revolo BiotherapeuticsPhase 2
SolrikitugUniquity BioPhase 2
CendakimabBristol Myers SquibbPhase 3
BarzolvolimabCelldex TherapeuticsPhase 2
VonoprazanPhathom PharmaceuticalsPhase 2